<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972062</url>
  </required_header>
  <id_info>
    <org_study_id>TEVA 540837</org_study_id>
    <nct_id>NCT00972062</nct_id>
  </id_info>
  <brief_title>Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis</brief_title>
  <acronym>MSSkin</acronym>
  <official_title>Herbal Therapy for Subcutaneous Injection Site Reactions in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Charlotte</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Teva Branded Pharmaceutical Products R&amp;D, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Charlotte</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if an herbal over-the-counter cream can decrease&#xD;
      skin site reactions in multiple sclerosis patients who currently take either Betaseron,&#xD;
      Copaxone or Rebif as their subcutaneous medication for managing their multiple sclerosis.&#xD;
      Injection site reactions have been indicated as one of the major reasons for discontinuing&#xD;
      treatment with the subcutaneous medications (Betaseron, Copaxone, and Rebif) for multiple&#xD;
      sclerosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Skin site reactions account for one of the most likely reasons for discontinuation of&#xD;
      subcutaneous injections of MS medications. It is imperative that additional methods be&#xD;
      determined to decrease the reactions and/or treat the reactions that occur. Individuals&#xD;
      continue to use over the counter preparations (e.g. Benadryl or steroid creams) or other&#xD;
      treatments recently described (warm compresses) to improve tolerance to the subcutaneous&#xD;
      injections and the reactions. Both short (3 to 6 months) and long term skin reactions have&#xD;
      been reported by patients. They complain about this at office visits and calls to nurses in&#xD;
      clinics or to those who teach injection technique. Recently, this investigator and a nurse&#xD;
      colleague found that an herbal cream (Bach's Rescue Remedy Cream) reduced the redness and&#xD;
      skin site reactions. A small investigator funded mini-pilot demonstrated a decrease in&#xD;
      resolution and in size of skin site reactions and satisfaction of herbal cream versus the&#xD;
      placebo cream. This proposed research study builds upon Moore's previous success that&#xD;
      documented significant decrease in injection site reactions by adding an air bubble to the&#xD;
      injection before injection, which is now described in the injection instructions of Copaxone,&#xD;
      Rebif, and Axonex. The specific hypotheses for this study as end points include:&#xD;
&#xD;
        1. The herbal cream will significantly decrease time of redness based on daily measure of&#xD;
           skin site reactions compared to placebo cream.&#xD;
&#xD;
        2. The herbal cream will decrease discomfort of skin site reactions as measured by a visual&#xD;
           analogue scale compared to the placebo cream.&#xD;
&#xD;
        3. Participants will indicate how the herbal cream has made a difference to their quality&#xD;
           of life based on a qualitative description of effects of skin site reactions before&#xD;
           herbal cream and following use of herbal cream&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Significant decrease in time and size of redness based on daily measure of skin site reactions using herbal cream compared to placebo cream.</measure>
    <time_frame>7 days from each injection</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Participants will indicate how the herbal cream has made a difference to their quality of life based on a qualitative description of effects of skin site reactions before herbal cream and following use of herbal cream</measure>
    <time_frame>2 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Multiple Sclerosis</condition>
  <arm_group>
    <arm_group_label>Placebo cream</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Cream base used in compounding medications into cream media</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Herbal Cream</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Herbal cream (Bach's Rescue Remedy Cream) applied to skin site reactions from MS medications</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Bach's Rescue Remedy Cream</intervention_name>
    <description>0.5 ml of cream applied to skin site reactions as needed</description>
    <arm_group_label>Herbal Cream</arm_group_label>
    <other_name>Rescue Cream</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo Cream</intervention_name>
    <description>Placebo cream 0.5 ml two times a day as needed</description>
    <arm_group_label>Placebo cream</arm_group_label>
    <other_name>Base cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Participants must demonstrate redness of skin site reactions&#xD;
&#xD;
          -  Must demonstrate accurate injection technique prior to initiating the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cannot read the flexible measure and record the results.&#xD;
&#xD;
          -  Are diagnosed with secondary progressive, primary progressive or Devic's MS.&#xD;
&#xD;
          -  Are not taking one of the three subcutaneous injections (Betaseron®, Copaxone® or&#xD;
             Rebif®).&#xD;
&#xD;
          -  Are pregnant.&#xD;
&#xD;
          -  Are younger than 18 years of age.&#xD;
&#xD;
          -  Are using combination therapy (e.g., 2 of the immunomodulators, chemotherapy)&#xD;
&#xD;
          -  Have allergies to any topical creams used on skin.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linda A Moore, EdD, APRN</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina at Charlotte</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of North Carolina at Charlotte</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28223</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Gaines AR, Varricchio F. Interferon beta-1b injection site reactions and necroses. Mult Scler. 1998 Apr;4(2):70-3.</citation>
    <PMID>9599336</PMID>
  </reference>
  <reference>
    <citation>Moore LA, Kaufman MD, Algozzine R, Irish N, Martin M, Posey CR. Adherence to therapy: using an evidence-based protocol. Rehabil Nurs. 2007 Nov-Dec;32(6):227-32.</citation>
    <PMID>18065143</PMID>
  </reference>
  <reference>
    <citation>Halper J, Harris C, Machler B. Manageing injection-site reactions in patients with MS. Multiple Sclerosis Counseling Points 1:1-10,2005</citation>
  </reference>
  <reference>
    <citation>Jolly H, Simpson K, Bishop B, Hunter H, Newell C, Denney D, Oleen-Burkey M. Impact of warm compresses on local injection-site reactions with self-administered glatiramer acetate. J Neurosci Nurs. 2008 Aug;40(4):232-9.</citation>
    <PMID>18727339</PMID>
  </reference>
  <reference>
    <citation>Samuel L, Lowenstein EJ. Recurrent injection site reactions from interferon beta 1-b. J Drugs Dermatol. 2006 Apr;5(4):366-7.</citation>
    <PMID>16673806</PMID>
  </reference>
  <verification_date>March 2012</verification_date>
  <study_first_submitted>September 2, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <last_update_submitted>March 6, 2012</last_update_submitted>
  <last_update_submitted_qc>March 6, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 7, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Subcutaneous injections</keyword>
  <keyword>Skin abnormalities</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Injection Site Reaction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

